404 related articles for article (PubMed ID: 20646533)
21. Curative effect of 1.88-mg and 3.75-mg gonadotrophin-releasing hormone agonist on stage III-IV endometriosis: Randomized controlled study.
Tang H; Wu R; Li X; Zhou Y; Liu Z; Wang C; Chen Y; Zhang F
J Obstet Gynaecol Res; 2017 Oct; 43(10):1550-1554. PubMed ID: 28707810
[TBL] [Abstract][Full Text] [Related]
22. Add-back therapy in the treatment of endometriosis-associated pain.
Zupi E; Marconi D; Sbracia M; Zullo F; De Vivo B; Exacustos C; Sorrenti G
Fertil Steril; 2004 Nov; 82(5):1303-8. PubMed ID: 15533351
[TBL] [Abstract][Full Text] [Related]
23. Hormonal Add-Back Therapy for Females Treated With Gonadotropin-Releasing Hormone Agonist for Endometriosis: A Randomized Controlled Trial.
DiVasta AD; Feldman HA; Sadler Gallagher J; Stokes NA; Laufer MR; Hornstein MD; Gordon CM
Obstet Gynecol; 2015 Sep; 126(3):617-627. PubMed ID: 26181088
[TBL] [Abstract][Full Text] [Related]
24. Clinical efficacy of add-back therapy in treatment of endometriosis: a meta-analysis.
Wu D; Hu M; Hong L; Hong S; Ding W; Min J; Fang G; Guo W
Arch Gynecol Obstet; 2014 Sep; 290(3):513-23. PubMed ID: 24728145
[TBL] [Abstract][Full Text] [Related]
25. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
26. Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women.
Zou S; Long Q; Zhang S; Han Y; Zhang W
Int J Clin Exp Med; 2013; 6(1):67-73. PubMed ID: 23236560
[TBL] [Abstract][Full Text] [Related]
27. Extending the treatment boundaries: Zoladex and add-back.
Schlaff WD
Int J Gynaecol Obstet; 1999 Feb; 64 Suppl 1():S25-31. PubMed ID: 10096462
[TBL] [Abstract][Full Text] [Related]
28. A Preliminary Study on the Effects of Black Cohosh Preparations on Bone Metabolism of Rat Models With GnRH-a-Induced Peri-Menopausal Symptoms.
Qin Z; Dong Z; Liu J; Zhong A; Bao M; Wang H; Yu H; Zhang S; Zhang W; Shen L; Wu J; Chen J
Front Endocrinol (Lausanne); 2022; 13():854345. PubMed ID: 35757412
[TBL] [Abstract][Full Text] [Related]
29. [Clinical application of luteinizing hormone releasing hormone agonist and its impact on bone metabolism].
Zhang M; He Y; Cao S
Zhonghua Fu Chan Ke Za Zhi; 1995 Jul; 30(7):398-401. PubMed ID: 7587574
[TBL] [Abstract][Full Text] [Related]
30. The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.
Soysal S; Soysal ME; Ozer S; Gul N; Gezgin T
Hum Reprod; 2004 Jan; 19(1):160-7. PubMed ID: 14688176
[TBL] [Abstract][Full Text] [Related]
31. Add-back therapy in the treatment of endometriosis: the European experience.
Edmonds DK
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():10-3. PubMed ID: 8916980
[TBL] [Abstract][Full Text] [Related]
32. Effects of different add-back regimens on hypoestrogenic problems by postoperative gonadotropin-releasing hormone agonist treatment in endometriosis.
Lee DY; Park HG; Yoon BK; Choi D
Obstet Gynecol Sci; 2016 Jan; 59(1):32-8. PubMed ID: 26866033
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis.
Kang JL; Wang XX; Nie ML; Huang XH
Gynecol Obstet Invest; 2010; 69(2):73-7. PubMed ID: 19923847
[TBL] [Abstract][Full Text] [Related]
34. High bone density in hyperandrogenic women: effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement.
Simberg N; Tiitinen A; Silfvast A; Viinikka L; Ylikorkala O
J Clin Endocrinol Metab; 1996 Feb; 81(2):646-51. PubMed ID: 8636283
[TBL] [Abstract][Full Text] [Related]
35. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
Cedars MI; Lu JK; Meldrum DR; Judd HL
Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
[TBL] [Abstract][Full Text] [Related]
36. Add-back therapy and gonadotropin-releasing hormone agonists in the treatment of patients with endometriosis: can a consensus be reached? Add-Back Consensus Working Group.
Surrey ES
Fertil Steril; 1999 Mar; 71(3):420-4. PubMed ID: 10065775
[TBL] [Abstract][Full Text] [Related]
37. Laparoscopic Surgery Combined with GnRH Agonist in Endometriosis.
Yang Y; Zhu W; Chen S; Zhang G; Chen M; Zhuang Y
J Coll Physicians Surg Pak; 2019 Apr; 29(4):313-316. PubMed ID: 30925951
[TBL] [Abstract][Full Text] [Related]
38. One year comparison between two add-back therapies in patients treated with a GnRH agonist for symptomatic endometriosis: a randomized double-blind trial.
Fernandez H; Lucas C; Hédon B; Meyer JL; Mayenga JM; Roux C
Hum Reprod; 2004 Jun; 19(6):1465-71. PubMed ID: 15105403
[TBL] [Abstract][Full Text] [Related]
39. GnRH-a-Induced Perimenopausal Rat Modeling and Black Cohosh Preparations' Effect on Rat's Reproductive Endocrine.
Chen J; Wang H; Dong Z; Liu J; Qin Z; Bao M; Yu H; Zhang S; Zhang W; Qi C; Wu J
Front Endocrinol (Lausanne); 2021; 12():683552. PubMed ID: 35002948
[TBL] [Abstract][Full Text] [Related]
40. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis.
Takaesu Y; Nishi H; Kojima J; Sasaki T; Nagamitsu Y; Kato R; Isaka K
J Obstet Gynaecol Res; 2016 Sep; 42(9):1152-8. PubMed ID: 27225336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
